An Open Label Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector (scAAV 2/8-LP1-hFIXco) For Gene Transfer in Hemophilia B
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2019
Price : $35 *
At a glance
- Drugs AAV-hFIX (Primary)
- Indications Haemophilia B
- Focus Adverse reactions
- 25 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 12 Jun 2032.
- 07 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2016 Planned End Date changed from 1 Jul 2031 to 1 Dec 2032.